Table 3 Summary of the overall treatment-related AEs reported in 24 months
From: OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
Adverse event observed | Number of patients/132 (%) |
|---|---|
Total treatment-related AEs | 23 (17.5) |
Injection-site pain | 4 (3.3) |
Neck pain | 5 (3.8) |
Musculoskeletal weakness | 5 (3.8) |
Eyelid ptosis | 4 (2.9) |
Headache | 5 (3.7) |